High-sensitive CRP as a predictive marker of long-term outcome in juvenile idiopathic arthritis

被引:9
作者
Alberdi-Saugstrup, Mikel [1 ,2 ,3 ]
Zak, Marek [1 ]
Nielsen, Susan [1 ]
Herlin, Troels [9 ]
Nordal, Ellen [4 ]
Berntson, Lillemor [5 ]
Fasth, Anders [6 ]
Rygg, Marite [7 ,8 ]
Mueller, Klaus [1 ,3 ]
机构
[1] Rigshosp, Dept Pediat & Adolescent Med, Copenhagen Univ Hosp, Copenhagen, Denmark
[2] Naestved Hosp, Dept Pediat, Naestved, Region Zealand, Denmark
[3] Rigshosp, Inst Inflammat Res, Copenhagen Univ Hosp, Copenhagen, Denmark
[4] Univ Hosp North Norway, Dept Pediat, Tromso, Norway
[5] Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden
[6] Univ Gothenburg, Dept Pediat, Gothenburg, Sweden
[7] Norwegian Univ Sci & Technol, Dept Lab Med Childrens & Womens Hlth, Trondheim, Norway
[8] St Olavs Hosp, Dept Pediat, Trondheim, Norway
[9] Aarhus Univ Hosp, Dept Pediat, Aarhus, Denmark
关键词
Arthritis; Juvenile idiopathic; High-sensitive CRP; Erythrocyte sedimentation rate; Follow-up; C-REACTIVE PROTEIN; ERYTHROCYTE SEDIMENTATION-RATE; RHEUMATOID-ARTHRITIS; DISEASE-ACTIVITY; PROGNOSTIC-FACTORS; SELECT CATEGORIES; INACTIVE DISEASE; REMISSION; CHILDREN; COHORT;
D O I
10.1007/s00296-017-3657-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To evaluate whether C-reactive protein (CRP), including variation within the normal range, is predictive of long-term disease outcome in Juvenile Idiopathic Arthritis (JIA). Consecutive patients with newly diagnosed JIA were included prospectively from defined geographic areas of the Nordic countries from 1997 to 2000. Inclusion criteria were availability of a baseline serum sample within 12 months after disease onset and 8-year clinical assessment data. Systemic onset JIA was not included. CRP was measured by high-sensitive ELISA (detection limit of 0.2 mg/l). One hundred and thirty participants with a median follow-up time of 97 months (range 95-100) were included. At follow-up, 38% of the patients were in remission off medication. Absence of remission was associated with elevated level of CRP at baseline (odds ratio (OR) 1.33, confidence interval (CI) 1.08-1.63, p = 0.007). By applying a cutoff at the normal upper limit (> 10 mg/l), the risk of not achieving remission was increased to an OR of 8.60 (CI 2.98-24.81, p < 0.001). Variations of CRP within the normal range had no predictive impact on disease activity at follow-up. Baseline levels of ESR were available in 80 patients (61%) and elevated ESR was associated with absence of remission in a multivariable logistic regression analysis (OR 2.32, CI 1.35-4.00, p = 0.002). This results of this study indicate that baseline CRP concentrations above 10 mg/l are predictive of a poor outcome at 8-year follow-up. We could not demonstrate any predictive value of CRP variations within the normal range.
引用
收藏
页码:695 / 703
页数:9
相关论文
共 38 条
[1]   Outcome following onset of juvenile idiopathic inflammatory arthritis: I. Frequency of different outcomes [J].
Adib, N ;
Silman, A ;
Thomson, W .
RHEUMATOLOGY, 2005, 44 (08) :995-1001
[2]  
Berntson L, 2003, J RHEUMATOL, V30, P2275
[3]   A 5-year prospective population-based study of juvenile chronic arthritis: onset, disease process, and outcome [J].
Bertilsson, L. ;
Andersson-Gare, B. ;
Fasth, A. ;
Forsblad-d'Elia, H. .
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2012, 41 (05) :379-382
[4]   C-Reactive Protein as a Risk Factor for Coronary Heart Disease: A Systematic Review and Meta-analyses for the US Preventive Services Task Force [J].
Buckley, David I. ;
Fu, Rongwei ;
Freeman, Michele ;
Rogers, Kevin ;
Helfand, Mark .
ANNALS OF INTERNAL MEDICINE, 2009, 151 (07) :483-W161
[5]  
BULL BS, 1993, J CLIN PATHOL, V46, P198
[6]  
De Benedetti F, 1998, J RHEUMATOL, V25, P203
[7]   Targeting the Interleukin-6 Receptor: A New Treatment for Systemic Juvenile Idiopathic Arthritis? [J].
de Benedetti, Fabrizio ;
Martini, Alberto .
ARTHRITIS AND RHEUMATISM, 2005, 52 (03) :687-693
[8]   Human C-reactive protein and the metabolic syndrome [J].
Devaraj, Sridevi ;
Singh, Uma ;
Jialal, Ishwarlal .
CURRENT OPINION IN LIPIDOLOGY, 2009, 20 (03) :182-189
[9]  
Esbjornsson AC, 2015, CLIN EXP RHEUMATOL
[10]  
FAGAN TJ, 1975, NEW ENGL J MED, V293, P257